ClinicalTrials.gg
CompletedNCT00119678Updated Sep 22, 2014Results posted

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

A Phase 2 interventional study of Abatacept and Placebo in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 52 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-22.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Enrollment
9th of 19
183 · median 125
Started
2005
the only one that year
Phase 2
7 of 20
none open now
Registered
1st of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 2, and was the 1st registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participants must be diagnosed with SLE and be experiencing an active lupus flare in at least one of three organ systems: skin (discoid lesions), inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a screening visit (arthritis)
  • Stable dose of prednisone (\<30mg) for at least one month

Exclusion criteria

Exclusion Criteria:

  • participants experiencing an active lupus flare in the kidney or central nervous systems
  • Treatment with a stable dose of azathioprine, mycophenolate mofetil, hydroxychloroquine, chloroquine, or methotrexate for less than three months prior to the study
  • participants with active viral or bacterial infections
  • participants with any other disease as a main diagnosis
  • Prior treatment with rituximab
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Abatacept + Prednisone

    Double Blind Period

    Drug: Abatacept · Drug: Prednisone

  • Placebo comparator
    Placebo + Prednisone

    Double Blind Period

    Drug: Placebo · Drug: Prednisone

  • Experimental
    Abatacept

    Open Label

    Drug: Abatacept

Interventions

  • Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months

    Also known as: Orencia

  • DrugPlacebo

    Injectable, intravenous, 0 mg, every 28 days, 12 months

  • Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months

  • Injectable, intravenous, 10 mg/kg, every 28 days

    Also known as: Orencia

06

What researchers measure

Primary outcomes

  1. Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare

    SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

    Time frame: From start of corticosteroid taper to Day 365

  2. Open Label Period (OL); Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs, Drug Related AEs or SAEs and Discontinued Due to AEs

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  3. OL; Number of Participants With Significant AEs of Special Interest

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  4. OL; Number of Participants With Marked Abnormalities (MAs) in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* lower limit of normal (LLN) or \>1.5\* upper limit of normal (ULN) (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  5. OL; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

    MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  6. OL; Number of Participants With MAs in Serum Chemistry: Alkaline Phosphatase (ALP), Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT), Gamma-glutamyl Transferase (GGT), Bilirubin(Total), Blood Urea Nitrogen (BUN), Creatinine

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  7. OL; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total), Protein (Total)

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95x LLN or \>1.05x ULN (if pre-Rx\<LLN, then \<0.95x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05x pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9x LLN or \>1.1xULN (if pre-Rx \<LLN, then \<0.9xpre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1xpre-Rx or \<LLN; Calcium (total): \<0.8xLLN or \>1.2xULN (if pre-Rx \<LLN, then \<0.75x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25x pre-Rx or \<LLN.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  8. OL; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides

    MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

  9. OL; Number of Participants With MAs in Urinalysis

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; Glomerular filtration rate (GFR): \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.

    Time frame: From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period

Secondary outcomes

  1. DB; Number of Participants With a New SLE Flare During the Initial 6 Months

    SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

    Time frame: From start of corticosteroid taper to 6 months.

  2. DB; Total Number of New SLE Flares Each Participant Experienced

    SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

    Time frame: From start of corticosteroid taper to Day 365

  3. DB; Median Number of Days to the First Occurrence of a New SLE Flare

    Elapsed days between start of corticosteroid taper \& first day of flare.Scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

    Time frame: From start of corticosteroid taper to confirmation of disease flare or the end of double-blind period

  4. DB; Number of Participants With a Change in the SLICC/ACR Damage Index at 1 Year Compared to Baseline

    SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.

    Time frame: From start of study drug treatment to Day 365

  5. DB; Number of Participants Who Died, Experienced AEs, Other SAEs or Discontinuations Due to AEs, Drug Related AEs

    AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  6. DB; Number of Participants With Significant AEs of Special Interest

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  7. DB; Number of Participants With MAs in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* LLN or \>1.5\* ULN (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  8. DB; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  9. DB: Number of Participants With MAs in Serum Chemistry: ALP, AST, ALT, GGT, Bilirubin (Total), BUN and Creatinine

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  10. DB; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total),Protein (Total)

    MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95\* LLN or \>1.05\* ULN (if pre-Rx \<LLN, then \<0.95\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05\* pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9\* LLN or \>1.1\* ULN (if pre-Rx \<LLN, then \<0.9\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1\* pre-Rx or \<LLN; Calcium (total): \<0.8\* LLN or \>1.2\* ULN (if pre-Rx \<LLN, then \<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25\* pre-Rx or \<LLN.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  11. DB; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dl or \>220 mg/dl; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  12. DB; Number of Participants With MAs in Urinalysis

    MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* pre-Rx, or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; GFR: \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  13. DB; Number of Participants With Clinically Significant Abnormal Vital Signs and/or Physical Examination Findings

    Vital signs assessments and physical examination were conducted throughout the study. Vital signs assessments included body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs or physical examination were clinically meaningful.

    Time frame: Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

  14. DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment

    Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept.

    Time frame: From Day 1 to Day 365

  15. OL; Number of Participants With a New SLE Flare

    SLE flares scored using BILAG:A:presence of =\>1 serious lupus features;B:more moderate features;C:mild symptomatic features;D:prior activity with no current symptoms due to active lupus;E:an organ that has never been involved.BILAG scores based on degrees of change in clinical features (1=improving,2=staying the same,3=worsening,4=new).New SLE flare means new BILAG A/B features in any organ system.Based on the recommendation of the Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

    Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

  16. OL; Number of Participants With a Change in the SLICC/ACR Damage Index at Year 2 Compared to Baseline

    SLICC/ACR damage index:measure of cumulative damage due to SLE.Damage=non-reversible change occurring since onset of lupus,ascertained by clinical assessment \& present for =\>6 months.Scores of SLICC/ACR index:1:single episode;2:repeated episodes at least 6 months apart.Change in score from baseline to 1 year presented as:no change,increase 1 (an increase in score of 1),increase \>1 (an increase in score of \>1).Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

    Time frame: From start of study drug therapy in open-label period (Day 365) and on Day 729.

  17. OL; Total Number of BILAG A Flares Each Participant Experienced

    Total number of BILAG A flares in any organ system after steroid tapering = new BILAG A features in any organ system. Scores defined as follows: None: participants with no BILAG A flare; 1: participants with 1 BILAG A flare or participants who discontinued without a new BILAG A flare were imputed as having one event. 2: participants with 2 BILAG A flares; 3 or \>3: participants with 3 or more BILAG A flares.Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

    Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

  18. OL; Area Under the Curve (AUC) for Prednisone or Prednisone Equivalent

    Total exposure to glucocorticosteroid was measured by the total prednisone or prednisone equivalent AUC. Based on the recommendation of the Data Monitoring Committee, the open-label, long-term extension period was terminated by the sponsor, for failure to meet the primary outcome measure for the double-blind period and because of an increase in SAEs in the abatacept treatment group. As such, these data were not analyzed.

    Time frame: From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

  19. OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment

    MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept.

    Time frame: After the first dose of open-label period

07

Results

Posted May 9, 2011

Participant flow

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneAbataceptPlacebo
Started12261
Randomized and treated12159
Randomized,treated, and analyzed11857
Completed8135
Not completed4126
Withdrew: Death10
Withdrew: Adverse event71
Withdrew: Lack of efficacy2112
Withdrew: Lost to follow-up12
Withdrew: Participant withdrew consent44
Withdrew: Participants not meeting study criteria01
Withdrew: Poor/non-compliance30
Withdrew: Pregnancy02
Withdrew: Not treated12
Withdrew: Site closed due to non-compliance32
Open-label Treatment Period
Participant flow — Open-label Treatment Period
MilestoneAbataceptPlacebo
Started1100
Completed00
Not completed1100
Withdrew: Death10
Withdrew: Adverse event30
Withdrew: Lack of efficacy90
Withdrew: Lost to follow-up30
Withdrew: Participant withdrew consent40
Withdrew: Participants not meeting study criteria20
Withdrew: Pregnancy10
Withdrew: Administrative reasons by sponsor870

Outcome measures

PrimaryDouble Blind Period (DB); Number of Participants Experiencing a New SLE Flare

SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved. Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

Time frame:
From start of corticosteroid taper to Day 365
Reported as:
Number · Participants
Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare
ParticipantsAbataceptPlacebo
Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare94 (72.4 to 86.9)47 (72.6 to 92.3)
SecondaryDB; Number of Participants With a New SLE Flare During the Initial 6 Months

SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

Time frame:
From start of corticosteroid taper to 6 months.
Reported as:
Number · Participants
DB; Number of Participants With a New SLE Flare During the Initial 6 Months
ParticipantsAbataceptPlacebo
DB; Number of Participants With a New SLE Flare During the Initial 6 Months75 (54.9 to 72.2)36 (50.6 to 75.7)
SecondaryDB; Total Number of New SLE Flares Each Participant Experienced

SLE flares scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of prednisone/prednisone-equivalent taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

Time frame:
From start of corticosteroid taper to Day 365
Reported as:
Number · Participants
DB; Total Number of New SLE Flares Each Participant Experienced
ParticipantsAbataceptPlacebo
None2410
14721
22110
>=31711
Inception treatment failure95
SecondaryDB; Median Number of Days to the First Occurrence of a New SLE Flare

Elapsed days between start of corticosteroid taper \& first day of flare.Scored using BILAG:A:presence of =\>1 serious;B:more moderate;C:mild symptomatic;D:prior activity,no current symptoms;E:organ that has never been involved.Calculated based on change during previous 4 weeks (1=improving,2=staying same,3=worsening,4=new).New SLE flare:first BILAG 'A' or 'B' event adjudicated to be flare following resolution of entry flare and/or start of corticosteroid taper.Inception treatment failure included (entry flare did not subside by Day 57/participant discontinued double-blind period before Day 29).

Time frame:
From start of corticosteroid taper to confirmation of disease flare or the end of double-blind period
Reported as:
Median · Days
DB; Median Number of Days to the First Occurrence of a New SLE Flare
DaysAbataceptPlacebo
DB; Median Number of Days to the First Occurrence of a New SLE Flare107.0 (81.0 to 125.0)92.0 (58.0 to 150.0)
Statistical analysis
  • Abatacept vs Placebo · Hazard ratio (hr): 1.1 · 95% CI 0.7 to 1.5Cox proportional-hazards model was used to estimate the hazard ratio of abatacept versus placebo for SLE disease flare. The 95% two-sided confidence interval was provided for the hazard ratio for treatment.
SecondaryDB; Number of Participants With a Change in the SLICC/ACR Damage Index at 1 Year Compared to Baseline

SLICC/ACR score or damage index is a measure of cumulative damage due to Systemic Lupus Erythematosus (SLE). Damage is defined as non-reversible change (not related to active inflammation) occurring since onset of lupus, ascertained by clinical assessment and present for at least 6 months. A score of 0=no damage, early damage is defined as ≥1. The total maximum score is 48, and increasing score indicates increasing disease severity.

Time frame:
From start of study drug treatment to Day 365
Reported as:
Number · participants
DB; Number of Participants With a Change in the SLICC/ACR Damage Index at 1 Year Compared to Baseline
participantsAbataceptPlacebo
No change101 (90.0 to 98.8)44 (86.6 to 100.0)
Increased 13 (0.6 to 8.0)2 (0.5 to 14.5)
Increased >13 (0.6 to 8.0)1 (0.1 to 11.3)
SecondaryDB; Number of Participants Who Died, Experienced AEs, Other SAEs or Discontinuations Due to AEs, Drug Related AEs

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Drug-related AEs: events with a certain; probable; possible; or missing relationship to the study therapy. Participants who discontinued the study due to an AE were recorded.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants Who Died, Experienced AEs, Other SAEs or Discontinuations Due to AEs, Drug Related AEs
participantsAbataceptPlacebo
Deaths00
AEs11054
SAEs244
All AEs Leading to Discontinuation103
Drug related AEs5928
SecondaryDB; Number of Participants With Significant AEs of Special Interest

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, AEs of special interest were associated with the use of immunomodulatory agents. Number of participants with infections, malignant neoplasms, pre-specified autoimmune disorders, acute infusional AEs and peri-infusional AEs were recorded.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With Significant AEs of Special Interest
participantsAbataceptPlacebo
Infections7138
Malignant neoplasms10
Pre-specified autoimmune disorders42
Acute-infusional AEs55
Peri-infusional AEs2713
SecondaryDB; Number of Participants With MAs in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* LLN or \>1.5\* ULN (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With MAs in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
participantsAbataceptPlacebo
Hemoglobin (n = 120, 58)11
Hematocrit (n=120, 58)11
Erythrocytes (n=120, 58)11
Platelet count (n= 118, 58)30
SecondaryDB; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
participantsAbataceptPlacebo
Leukocytes (n = 120, 58)2611
Neutrophils+bands (absolute) (n = 120, 59)82
Lymphocytes (absolute) (n = 120, 59)4630
Monocytes (absolute) (n = 120, 59)10
Basophils (absolute) (n = 120, 59)00
Eosinophils (absolute) (n = 120, 59)62
SecondaryDB: Number of Participants With MAs in Serum Chemistry: ALP, AST, ALT, GGT, Bilirubin (Total), BUN and Creatinine

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB: Number of Participants With MAs in Serum Chemistry: ALP, AST, ALT, GGT, Bilirubin (Total), BUN and Creatinine
participantsAbataceptPlacebo
ALP (n = 120, 59)20
AST (n = 120, 59)30
ALT (n = 120, 59)20
GGT (n = 120, 59)33
Bilirubin (total) (n = 120, 59)00
BUN (n = 120, 59)43
Creatinine (n = 120, 59)64
SecondaryDB; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total),Protein (Total)

MAs are laboratory measurements marked as abnormal as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95\* LLN or \>1.05\* ULN (if pre-Rx \<LLN, then \<0.95\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05\* pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9\* LLN or \>1.1\* ULN (if pre-Rx \<LLN, then \<0.9\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1\* pre-Rx or \<LLN; Calcium (total): \<0.8\* LLN or \>1.2\* ULN (if pre-Rx \<LLN, then \<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25\* pre-Rx or \<LLN.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total),Protein (Total)
participantsAbataceptPlacebo
Sodium (serum) (n = 120, 59)10
Potassium (serum) (n = 120, 59)11
Chloride (serum) (n = 120, 59)00
Calcium (total) (n= 120, 59)00
Protein (total) (n = 120, 59)10
SecondaryDB; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dl or \>220 mg/dl; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
participantsAbataceptPlacebo
Glucose (serum) (n = 120, 59)2710
Glucose, fasting (n = 77, 37)51
Albumin (n = 120, 59)41
Cholesterol (total) (n = 118, 58)00
Triglycerides (n = 75, 36)00
Triglycerides (fasting) (n = 64, 34)00
SecondaryDB; Number of Participants With MAs in Urinalysis

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, RBC, WBC: \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* pre-Rx, or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; GFR: \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier
Reported as:
Number · participants
DB; Number of Participants With MAs in Urinalysis
participantsAbataceptPlacebo
Protein (n = 120, 58)159
Glucose (n = 120, 58)12
Blood (n = 120, 58)3918
Leukocyte esterase (n = 107, 51)238
RBC (n = 107, 55)3816
WBC (n = 115, 54)6126
Protein, 24 hours (n = 89, 40)41
GFR (n = 120, 59)74
Protein/creatinine ratio (n = 119, 58)114
SecondaryDB; Number of Participants With Clinically Significant Abnormal Vital Signs and/or Physical Examination Findings

Vital signs assessments and physical examination were conducted throughout the study. Vital signs assessments included body temperature, respiratory rate, blood pressure (systolic and diastolic) and heart rate. The investigator used his/her clinical judgment to decide whether or not abnormalities in vital signs or physical examination were clinically meaningful.

Time frame:
Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier

No measurements were reported for this outcome.

PrimaryOpen Label Period (OL); Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs, Drug Related AEs or SAEs and Discontinued Due to AEs

AEs: any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to an AE were recorded. Drug-related AEs or SAEs: events with a relationship to the study therapy of certain; probable; possible; or missing.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
Open Label Period (OL); Number of Participants Who Died, Experienced Adverse Events (AEs), Serious AEs, Drug Related AEs or SAEs and Discontinued Due to AEs
participantsAbatacept
Deaths1
AEs97
SAEs21
All AEs Leading to Discontinuation3
Drug related AEs49
Drug related SAEs11
PrimaryOL; Number of Participants With Significant AEs of Special Interest

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition (even if not caused by the study drug). For this study, it was decided that AEs of particular importance were associated with the use of immunomodulatory agents. Number of participants with infections, malignant Neoplasms, pre-specified autoimmune disorders, acute-infusional AEs and peri-infusional AEs were recorded.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With Significant AEs of Special Interest
participantsAbatacept
Infections82
Malignant neoplasms1
Pre-specified autoimmune disorders4
Acute-infusional AEs3
Peri-infusional AEs15
PrimaryOL; Number of Participants With Marked Abnormalities (MAs) in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Hemoglobin: \>3 g/dL decrease from pre-treatment (pre-Rx) value; hematocrit: \<0.75\* pre-Rx value; erythrocyte count: \<0.75\* pre-Rx value; platelet count: \<0.67\* lower limit of normal (LLN) or \>1.5\* upper limit of normal (ULN) (or, if pre-Rx value \<LLN, then \<0.5\* pre-Rx value or \<100000/mm\^3).

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With Marked Abnormalities (MAs) in Hematology: Hemoglobin, Hematocrit, Erythrocytes and Platelet Count
participantsAbatacept
Hemoglobin (n = 110)2
Hematocrit (n = 110)3
Erythrocytes (n = 110)2
Platelet count (n = 108)3
PrimaryOL; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)

MMAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following hematology MA definitions specify the criteria for the data presented. Leukocytes: \<0.75\* LLN or \>1.25\* ULN (or, if pre-Rx value \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx value \>ULN, then \>1.2\* pre-Rx or \<LLN; Neutrophils+bands (absolute): \<1.00\* 10\^3 cells/microliter (c/uL); Lymphocytes (absolute): \<0.75\* 10\^3 c/uL or \>7.50\* 10\^3 c/uL; Monocytes (absolute): \>2000/mm\^3; Basophils (absolute): \>0.40\* 10\^3 c/uL; Eosinophils (absolute): \>0.75\* 10\^3 c/uL.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With MAs in Hematology: Leukocytes, Neutrophils + Bands (Absolute), Lymphocytes (Absolute), Monocytes (Absolute), Basophils (Absolute) and Eosinophils (Absolute)
participantsAbatacept
Leukocytes18
Neutrophils+bands (absolute)6
Lymphocytes (absolute)32
Monocytes (absolute)0
Basophils (absolute)0
Eosinophils (absolute)3
PrimaryOL; Number of Participants With MAs in Serum Chemistry: Alkaline Phosphatase (ALP), Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT), Gamma-glutamyl Transferase (GGT), Bilirubin(Total), Blood Urea Nitrogen (BUN), Creatinine

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria. ALP, GGT: \>2\* ULN (if pre-Rx \>ULN, then \>3\* pre-Rx); AST, ALT: \>3\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx). Bilirubin (total): \>2\* ULN (if pre-Rx \>ULN, then \>4\* pre-Rx), BUN:\>2\* pre-Rx; Creatinine:\>1.5\* pre-Rx.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With MAs in Serum Chemistry: Alkaline Phosphatase (ALP), Aspartate-aminotransferase (AST), Alanine-aminotransferase (ALT), Gamma-glutamyl Transferase (GGT), Bilirubin(Total), Blood Urea Nitrogen (BUN), Creatinine
participantsAbatacept
ALP0
AST3
ALT4
GGT6
Bilirubin (total)0
BUN3
Creatinine7
PrimaryOL; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total), Protein (Total)

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Sodium (serum): \<0.95x LLN or \>1.05x ULN (if pre-Rx\<LLN, then \<0.95x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.05x pre-Rx or \<LLN); Potassium (serum), Chloride (serum), protein (total): \<0.9x LLN or \>1.1xULN (if pre-Rx \<LLN, then \<0.9xpre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.1xpre-Rx or \<LLN; Calcium (total): \<0.8xLLN or \>1.2xULN (if pre-Rx \<LLN, then \<0.75x pre-Rx or \>ULN. If pre-Rx \>ULN, then \>1.25x pre-Rx or \<LLN.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With MAs in Serum Chemistry: Sodium (Serum), Potassium (Serum), Chloride (Serum), Calcium (Total), Protein (Total)
participantsAbatacept
Sodium (serum)0
Potassium (serum)7
Chloride (serum)0
Calcium (total)1
Protein (total)4
PrimaryOL; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides

MAs are laboratory measurements marked as abnormal, as per pre-defined study criteria, at any study time point. The following serum chemistry MA definitions specify MA criteria, Glucose: \<65 mg/dL or \>220 mg/dL; Glucose (fasting serum): \<0.8\* LLN or \>1.5 ULN (if pre-Rx \<LLN, then \<0.8\* pre-Rx or \>ULN. If pre-Rx \>ULN, then \>2.0\* pre-Rx or \<LLN; Albumin: \<0.9\* LLN (if pre-Rx \<LLN, then \<0.75 \* pre-Rx); cholesterol (total): \>2\* pre-Rx; triglycerides: \>=2.5\* ULN, or if pre Rx\>ULN then use \>2.5\* pre Rx; fasting triglycerides: \>=2.0\* ULN, or if pre Rx\>ULN then use \>2.0\* pre Rx.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With MAs in Serum Chemistry: Glucose (Serum), Glucose (Fasting Serum), Albumin, Cholesterol (Total), Triglycerides, Fasting Triglycerides
participantsAbatacept
Glucose (serum) (n = 110)21
Glucose (fasting serum) (n = 55)6
Albumin (n = 110)6
Cholesterol (total) (n = 15)0
Triglycerides (n = 10)0
Triglycerides (fasting) (n = 9)0
PrimaryOL; Number of Participants With MAs in Urinalysis

MAs are laboratory measurements marked as abnormal, per pre-defined study criteria, at any study time point. The following definitions specify the criteria for MAs in urinalysis, Protein, glucose, blood, Leukocyte esterase, red blood cells (RBC), white blood cells (WBC): \>=2+ (or, if value \>=4, or if pre-Rx value = 0 or 0.5, then \>= 2\* or if pre-Rx value =1, then \>=3, or if pre-Rx = 2 or 3, then \>=4); protein (24 hour urine): \>1000 mg/24 hrs and \>=2\* pre-Rx; Glomerular filtration rate (GFR): \<=60 mL/min/1.73m\^2 or \> 15% change from baseline; Protein/creatinine ratio: \> 100 mg/mmol.

Time frame:
From start of study drug therapy in open-label period (Day 365) up to 56 days after the last dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With MAs in Urinalysis
participantsAbatacept
Protein (n = 110)12
Glucose (n= 110)0
Blood (n = 110)41
Leukocyte esterase (n = 104)28
WBC (n = 105)57
RBC (n = 101)35
GFR (n = 110)9
Protein/creatinine ratio (n = 109)10
SecondaryDB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment

Electrochemiluminescence (ECL) immunoassay based on Meso Scale Discovery (MSD) technology was used to detect antibodies specific for CTLA4-T and for abatacept.

Time frame:
From Day 1 to Day 365
Reported as:
Number · participants
DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
participantsAbatacept
DB; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment2
SecondaryOL; Number of Participants With a New SLE Flare

SLE flares scored using BILAG:A:presence of =\>1 serious lupus features;B:more moderate features;C:mild symptomatic features;D:prior activity with no current symptoms due to active lupus;E:an organ that has never been involved.BILAG scores based on degrees of change in clinical features (1=improving,2=staying the same,3=worsening,4=new).New SLE flare means new BILAG A/B features in any organ system.Based on the recommendation of the Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

Time frame:
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

No measurements were reported for this outcome.

SecondaryOL; Number of Participants With a Change in the SLICC/ACR Damage Index at Year 2 Compared to Baseline

SLICC/ACR damage index:measure of cumulative damage due to SLE.Damage=non-reversible change occurring since onset of lupus,ascertained by clinical assessment \& present for =\>6 months.Scores of SLICC/ACR index:1:single episode;2:repeated episodes at least 6 months apart.Change in score from baseline to 1 year presented as:no change,increase 1 (an increase in score of 1),increase \>1 (an increase in score of \>1).Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

Time frame:
From start of study drug therapy in open-label period (Day 365) and on Day 729.

No measurements were reported for this outcome.

SecondaryOL; Total Number of BILAG A Flares Each Participant Experienced

Total number of BILAG A flares in any organ system after steroid tapering = new BILAG A features in any organ system. Scores defined as follows: None: participants with no BILAG A flare; 1: participants with 1 BILAG A flare or participants who discontinued without a new BILAG A flare were imputed as having one event. 2: participants with 2 BILAG A flares; 3 or \>3: participants with 3 or more BILAG A flares.Based on recommendation of Data Monitoring Committee, open-label period terminated, as failed to meet primary outcome measure for double-blind period/increase in SAEs in abatacept group.

Time frame:
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

No measurements were reported for this outcome.

SecondaryOL; Area Under the Curve (AUC) for Prednisone or Prednisone Equivalent

Total exposure to glucocorticosteroid was measured by the total prednisone or prednisone equivalent AUC. Based on the recommendation of the Data Monitoring Committee, the open-label, long-term extension period was terminated by the sponsor, for failure to meet the primary outcome measure for the double-blind period and because of an increase in SAEs in the abatacept treatment group. As such, these data were not analyzed.

Time frame:
From start of study drug therapy in open-label period (Day 365), Day 393, 421, 449 and every 28 days thereafter till Day 729.

No measurements were reported for this outcome.

SecondaryOL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment

MSD technology was used to detect antibodies specific for CTLA4-T and for abatacept.

Time frame:
After the first dose of open-label period
Reported as:
Number · participants
OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment
participantsAbatacept
OL; Number of Participants With Antibodies Specific for CTLA4-T and Abatacept, Following Abatacept Treatment30

Adverse events

Collected over Events recorded at each participant encounter, from start of study drug therapy up to Day 337, including up to 56 days after the last dose or up to the first dose of open-label, whichever occurred earlier.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept—24/121 (19.8%)90/121 (74.4%)
Placebo—4/59 (6.8%)41/59 (69.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventAbataceptPlacebo
SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders3/1211/59
PYREXIAGeneral disorders3/1210/59
LUPUS VASCULITISVascular disorders0/1211/59
PSYCHOTIC DISORDERPsychiatric disorders1/1211/59
HEADACHENervous system disorders0/1211/59
PERITONITIS LUPUSGastrointestinal disorders0/1211/59
BRONCHOPNEUMONIAInfections and infestations0/1211/59
ANGIOEDEMASkin and subcutaneous tissue disorders0/1211/59
PERICARDITISCardiac disorders2/1210/59
DEPRESSIONPsychiatric disorders1/1210/59
Most frequent other events
Showing 10 of 29
Most frequent other events
EventAbataceptPlacebo
HEADACHENervous system disorders25/12110/59
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations25/1219/59
BACK PAINMusculoskeletal and connective tissue disorders15/1215/59
NASOPHARYNGITISInfections and infestations3/1217/59
DIARRHOEAGastrointestinal disorders14/1214/59
URINARY TRACT INFECTIONInfections and infestations13/1215/59
NAUSEAGastrointestinal disorders12/1214/59
PHARYNGOLARYNGEAL PAINRespiratory, thoracic and mediastinal disorders12/1212/59
ABDOMINAL PAINGastrointestinal disorders11/1210/59
ARTHRALGIAMusculoskeletal and connective tissue disorders11/1214/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)AbataceptPlaceboTotal
Median38.0 ± 12.7636.0 (19.0 to 65.0)38.0 (18.0 to 71.0)
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female10455159
Male14216
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AbataceptPlaceboTotal
White7439113
Black/African American12416
American Indian/Alaska Native101
Asian281341
Other races314
Weight
Weight(kilograms)AbataceptPlaceboTotal
Mean68.630 ± 18.71769.000 ± 14.79068.750 ± 17.493
Systemic Lupus International Collaborative Clinics/American College of Rheumatology(SLICC/ACC) score
Systemic Lupus International Collaborative Clinics/American College of Rheumatology(SLICC/ACC) score(participants)AbataceptPlaceboTotal
Overall SLICC/ACR score 08238120
Overall SLICC/ACR score 1121123
Overall SLICC/ACR score 215520
Overall SLICC/ACR score >2617
Overall SLICC/ACR score unavailable325
08

Study locations

52 sites
  • University Of Arizona Arthritis Center
    Tucson, Arizona 85724, United States
  • Office Of Geoffrey S. Dolan, Md
    Long Beach, California 90808, United States
  • 8737 Beverly Blvd.
    Los Angeles, California 90048, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Cria Research
    Ft. Lauderdale, Florida 33334, United States
  • The University Of Chicago
    Chicago, Illinois 60637, United States
  • Kentuckiana Center For Better Bone And Joint Health
    Louisville, Kentucky 40202, United States
  • Kelly, Timothy
    Las Vegas, Nevada 89128, United States
  • Suny Downstate Medical Center
    Brooklyn, New York 11203, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Ok Medical Research Foundations
    Oklahoma City, Oklahoma 73104, United States
  • Texas Research Center
    Sugarland, Texas 77479, United States
  • Local Institution
    Cairns, Queensland 4870, Australia
  • Local Institution
    Maroochydore, Queensland 4558, Australia
  • Local Institution
    Clayton, Victoria 3168, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Bruxelles, 1200, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Goiania, Goias 74050, Brazil
  • Local Institution
    Curitiba, Parana 80060, Brazil
  • Local Institution
    Rio De Janeiro - Rj, Rio De Janeiro 20551, Brazil
  • Local Institution
    Campinas, Sao Paulo 13083, Brazil
  • Local Institution
    São Paulo, Sao Paulo 04027, Brazil
  • Local Institution
    Sao Paulo, 01246, Brazil
  • Local Institution
    Sao Paulo, 04023900, Brazil
  • Local Institution
    Sao Paulo, 04233, Brazil
  • Local Institution
    Vancouver, British Columbia V5Z 1L7, Canada
  • Local Institution
    Winnipeg, Manitoba R3A 1M4, Canada
  • Local Institution
    Bordeaux Cedex, 33076, France
  • Local Institution
    Montpellier Cedex 5, 34295, France
  • Local Institution
    Paris Cedex 14, 75679, France
  • Local Institution
    Berlin, 13125, Germany
  • Local Institution
    Duesseldorf, 40225, Germany
  • Local Institution
    Freiburg, 79106, Germany
  • Local Institution
    Ferrara, 44100, Italy
  • Local Institution
    Seoul, Sungdong-Gu 133-792, Korea, Republic of
  • Local Institution
    Seoul, 110-744, Korea, Republic of
  • Local Institution
    Seoul, 137-040, Korea, Republic of
  • Local Institution
    Seoul, 138-736, Korea, Republic of
  • Local Institution
    Mexico City, Distrito Federal 06726, Mexico
  • Local Institution
    Morelia, Michioacan 58070, Mexico
  • Local Institution
    Aguascalientes, 20000, Mexico
  • Local Institution
    Ponce, 00716, Puerto Rico
  • Local Institution
    Berea, Kwa Zulu Natal 4001, South Africa
  • Local Institution
    Panorama, Western Cape 7506, South Africa
  • Local Institution
    Kaohsiung, 833, Taiwan
  • Local Institution
    Taichung, 407, Taiwan
  • Local Institution
    Taipei, 105, Taiwan
  • Local Institution
    Taipei, 11217, Taiwan
  • Local Institution
    London, Greater London SE1 7EX, United Kingdom
09

References and documents

Publications

  • Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG. Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12. PubMed 29534336 ↗
  • Bandyopadhyay S, Connolly SE, Jabado O, Ye J, Kelly S, Maldonado MA, Westhovens R, Nash P, Merrill JT, Townsend RM. Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Sci Med. 2017 Jul 28;4(1):e000206. doi: 10.1136/lupus-2017-000206. eCollection 2017. PubMed 29214034 ↗
  • Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077-87. doi: 10.1002/art.27601. PubMed 20533545 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 14, 2005
Start
Sep 2005
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
May 9, 2011
Last update
Sep 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00119678
Responsible party
Sponsor
First posted
Jul 14, 2005
Start date
Sep 2005
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
May 9, 2011
Last update
Sep 22, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion